CMC2.24
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


CMC2.24
Description :
CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC50s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis[1][2][3].Product Name Alternative :
TRB-N0224UNSPSC :
12352005Hazard Statement :
H302, H315, H319Target :
Apoptosis; MMP; RasType :
Reference compoundRelated Pathways :
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/ProteaseApplications :
COVID-19-immunoregulationField of Research :
Cancer; Inflammation/ImmunologyAssay Protocol :
https://www.medchemexpress.com/cmc2-24.htmlPurity :
97.48Solubility :
DMSO : < 1 mg/mLSmiles :
O=C(NC1=CC=CC=C1)C(C(/C=C/C2=CC=C(O)C=C2)=O)C(/C=C/C3=CC=C(O)C=C3)=OMolecular Formula :
C26H21NO5Molecular Weight :
427.45Precautions :
H302, H315, H319References & Citations :
[1]Mallangada NA, et al. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. Mol Carcinog. 2018;57 (9) :1130-1143.|[2]Zhou Y, et al. Chemically modified curcumin (CMC2.24) alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis. J Mol Med (Berl) . 2020;98 (10) :1479-1491.|[3]Zhang Y, et al. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem. 2012;19 (25) :4348-4358.Shipping Conditions :
Blue IceStorage Conditions :
-20°C (Powder, protect from light)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedIsoform :
MMP-1; MMP-12; MMP-13; MMP-14; MMP-2; MMP-3; MMP-7; MMP-8; MMP-9CAS Number :
[1255639-43-0]

